22482-43-5

Basic information

• Product Name: 2,6-DICHLORO-OMEGA-NITROSTYRENE
• Synonyms: 1,3-dichloro-2-(2-nitroethenyl)-benzen;1,3-dichloro-2-(2-nitroethenyl)benzene;TRANS-2,6-DICHLORO-BETA-NITROSTYRENE;2,6-DICHLORO-W-NITROSTYRENE;2,6-DICHLORO-OMEGA-NITROSTYRENE;2',6'-DICHLORO-BETA-NITROSTYRENE;2,6-DICHLORO-BETA-NITROSTYRENE;1-(2,6-DICHLOROPHENYL)-2-NITROETHYLENE
• CAS NO: 22482-43-5
• Molecular Formula: C₈H₅Cl₂NO₂
• Molecular Weight: 218.04
• EINECS: -0
• Mol File: 22482-43-5.mol
• Article Data: 8

Chemical Properties

• Melting Point: 63-67 °C(lit.)
• Boiling Point: 330.6 °C at 760 mmHg
• Flash Point: 153.7 °C
• Appearance: /
• Density: 1.447 g/cm³
• Vapor Pressure: 0.000316mmHg at 25°C
• Refractive Index: 1.626
• CAS DataBase Reference: 2,6-DICHLORO-OMEGA-NITROSTYRENE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-DICHLORO-OMEGA-NITROSTYRENE(22482-43-5)
• EPA Substance Registry System: 2,6-DICHLORO-OMEGA-NITROSTYRENE(22482-43-5)

Safety Data

• Hazard Codes: Xn,N,Xi
• Statements: 22-51/53
• Safety Statements: 61
• RIDADR: UN 3077 9/PG 3
• WGK Germany: 2
• Hazardous Substances Data: 22482-43-5(Hazardous Substances Data)

Usage

Chemical Properties

dark yellow crystalline powder

InChI:InChI=1/C8H5Cl2NO2/c9-7-2-1-3-8(10)6(7)4-5-11(12)13/h1-5H

Upstream product

• 75-52-5 nitromethane 
• 83-38-5 2,6-dichlorobenzaldehyde 

Downstream Products

• 50368-43-9 3-butyl-5-(2,6-dichloro-phenyl)-2-thioxo-[1,3,4]thiadiazinan-6-one oxime 
• 50368-44-0 5-(2,6-dichloro-phenyl)-3-(2-hydroxy-ethyl)-2-thioxo-[1,3,4]thiadiazinan-6-one oxime 
• 1185770-47-1 t-butyl 1-(1-(2,6-dichlorophenyl)-2-nitroethyl)-2-oxocyclopentanecarboxylate 
• 1195190-68-1 (3S,4R,5S)-3-(4-chlorophenyl)-5-(2,6-dichlorophenyl)-4-nitrocyclohexanone 
• 1195190-66-9 (3S,4R,5S)-3-(2,6-dichlorophenyl)-4-nitro-5-phenylcyclohexanone 
• 1296198-96-3 (E)-3-(2,6-dichlorophenyl)-2-(hydroxyimino)-5-methyl-2,3-dihydrofuro[3,2-c]quinolin-4(5H)-one 

Relevant articles and documents

Skeletally Tunable Seven-Membered-Ring Fused Pyrroles

We describe a copper-mediated method that enables the synthesis of seven-membered-ring fused pyrroles (7-mrFPs). The protocol proceeds via an in situ spiro-intermediate ring expansion and tolerates a library of 7-mrFP derivatives with a broad range of functional groups in a simple step with tangible parameters and substrate adaptations. These rare 7-mrFPs are now accessible on a millimolar scale, and selected examples exhibit high antioxidant activity.

Compound containing FXR agonist, and preparation method and application thereof

The invention belongs to the technical field of medicines, and concretely relates to a compound containing an FXR agonist, represented by general formula (I), or a pharmaceutically acceptable salt thereof, a preparation method of the compounds, a pharmaceutical composition and a pharmaceutical preparation containing the compounds, and an application of the compounds in the preparation of drugs used for treating and/or preventing FXR mediated diseases. R, R, R, R, m, n, p, q, T, L1-L2 and A ring or B ring in the formula (I) are defined in the description.

Comprehensive evaluation of antioxidant effects of Japanese Kampo medicines led to identification of Tsudosan formulation as a potent antioxidant agent

Oxidative stress due to the overproduction of reactive oxygen species plays an important role in the pathogenesis of various diseases. In the present study, we comprehensively evaluated the antioxidant activities of 147 oral formulations of Japanese traditional herbal medicines (Kampo medicines), representing the entire panel of oral Kampo medicines listed in the Japanese National Health Insurance Drug List, using in vitro radical scavenging assays, including the 2,2-diphenyl-1-picrylhydrazyl free radical scavenging activity assay, the superoxide anion scavenging activity assay, and the oxygen radical absorption capacity assay. Three of the formulations tested, namely, Tsudosan, Daisaikoto, and Masiningan, showed the most potent in vitro antioxidant activities and were selected for further investigation of their intracellular and in vivo antioxidant effects. The results of the 2′,7′-dichlorodihydrofluorescin diacetate assay demonstrated that all three Kampo medicines significantly inhibited hydrogen peroxide-induced oxidative stress in human hepatocellular liver carcinoma HepG2 cells. In addition, Tsudosan significantly increased the serum biological antioxidant potential values when orally administrated to mice, indicating that it also had in vivo antioxidant activity. The potent antioxidant activity of Tsudosan may be one of the mechanisms closely correlated to its clinical usage against blood stasis.